TY - JOUR
T1 - Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region
T2 - A single-center Asian experience
AU - Sun, Cheuk Kwan
AU - Chen, Chao Long
AU - Concejero, Allan M.
AU - Wang, Chih Chi
AU - Wang, Shih Ho
AU - Liu, Yueh Wei
AU - Yang, Chin Hsiang
AU - Yong, Chee Chien
PY - 2011/1
Y1 - 2011/1
N2 - From March 1984 to November 2008, we performed 539 primary liver transplantations (LTs). Nineteen (19, 3.5%) were transplanted for end-stage liver disease secondary to primary biliary cirrhosis (PBC). There were 17 (89%) female and 2 (11%) male recipients. The overall mean age was 50.3±6.3yr. The mean model for end-stage liver disease, and Child-Turcotte-Pugh scores were 20.7±2.1, and 11.0±0.5, respectively. There were 2 (11%) United Network for Organ Sharing status 3, 16 (84%) 2B, and 1 (5%) 2A patients. Fourteen patients (14, 73.7%) underwent living donor LT, and five patients (26.3%) received deceased donor LT. The primary immunosuppression consisted of cyclosporine (n=5) and tacrolimus (n=14). Liver function returned to normal one month after transplantation. The overall mean follow-up was 5.8±0.8yr (range, four months to 15.7yr). The overall one-, three-, and five-yr survival rates were 94.7%, 89.2%, and 89.2%, respectively. Without hepatitis B virus (HBV) prophylaxis, one patient acquired de novo HBV infection after receiving a graft from an anti-HBc(+) donor. Another patient developed recurrent hepatitis C infection and expired 25months after transplantation. Our results showed that HBV prophylaxis was effective not only against de novo infection, but it also worked on pre-transplant HBV carrier with PBC and helped in virus clearance.
AB - From March 1984 to November 2008, we performed 539 primary liver transplantations (LTs). Nineteen (19, 3.5%) were transplanted for end-stage liver disease secondary to primary biliary cirrhosis (PBC). There were 17 (89%) female and 2 (11%) male recipients. The overall mean age was 50.3±6.3yr. The mean model for end-stage liver disease, and Child-Turcotte-Pugh scores were 20.7±2.1, and 11.0±0.5, respectively. There were 2 (11%) United Network for Organ Sharing status 3, 16 (84%) 2B, and 1 (5%) 2A patients. Fourteen patients (14, 73.7%) underwent living donor LT, and five patients (26.3%) received deceased donor LT. The primary immunosuppression consisted of cyclosporine (n=5) and tacrolimus (n=14). Liver function returned to normal one month after transplantation. The overall mean follow-up was 5.8±0.8yr (range, four months to 15.7yr). The overall one-, three-, and five-yr survival rates were 94.7%, 89.2%, and 89.2%, respectively. Without hepatitis B virus (HBV) prophylaxis, one patient acquired de novo HBV infection after receiving a graft from an anti-HBc(+) donor. Another patient developed recurrent hepatitis C infection and expired 25months after transplantation. Our results showed that HBV prophylaxis was effective not only against de novo infection, but it also worked on pre-transplant HBV carrier with PBC and helped in virus clearance.
KW - Anti-HBc(+) grafts
KW - Liver transplantation
KW - Living donor liver transplantation
KW - Primary biliary cirrhosis
KW - Viral hepatitis
UR - http://www.scopus.com/inward/record.url?scp=79551717809&partnerID=8YFLogxK
U2 - 10.1111/j.1399-0012.2010.01288.x
DO - 10.1111/j.1399-0012.2010.01288.x
M3 - 文献综述
C2 - 20560991
AN - SCOPUS:79551717809
SN - 0902-0063
VL - 25
SP - 47
EP - 53
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 1
ER -
